🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer oncodaily.com/url/239731 Giampaolo Bianchini JAMA Network Michail ignatiadis Heather McArthur, MD, MPH, FASCO Renato Azambuja De lima e Otto Metzger #Cancer #BCSM #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

2025 FASCO Recipients Part – 2 Heather McArthur, MD, MPH, FASCO Ryan Nipp, MD, MPH, FASCO Sara Tolaney Anne Tsao, MD, MBA Claudine Isaacs oncodaily.com/career/241649 #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews

“We hope that these results inform treatment decisions and, in turn, improve outcomes for patients with breast cancer, ultimately improving cure rates,” said Heather McArthur, MD, MPH. #bcsm | Heather McArthur, MD, MPH, FASCO cancernetwork.com/view/neoadjuva…

Don't miss this recent JAMA pub on Adjuvant #Atezolizumab for Early #TripleNegativeBreastCancer, results from the ALEXANDRA/IMpassion030 Randomized Clinical Trial. 🔓pubmed.ncbi.nlm.nih.gov/39883436/ ✍️Michail ignatiadis Otto Metzger Heather McArthur, MD, MPH, FASCO Evandro de Azambuja, MD, PhD Gustavo Werutsky

Discover how personalised care is on a path to revolutionise breast cancer treatment in the latest episode of Onc Now. Host Jonathan Sackier is joined by Heather McArthur to explore the latest breakthroughs in targeted therapies and more. 🔗: hubs.la/Q039qDhD0

Watch below as Heather McArthur, MD, MPH, FASCO discusses the latest breakthroughs in targeted therapies for #breastcancer on the Onc Now podcast.

Don’t Miss Out on a Premier Breast Cancer Conference! We are excited to announce the inaugural Breast Cancer US Focus Meeting, set for April 25-26, 2025, in Boston, MA. Chaired by Dr. Virginia Kaklamani and Dr. Sara M. Tolaney, this exclusive event will assemble the foremost

Breakthroughs in TNBC: Immunotherapy & immune checkpoint inhibitors are revolutionizing treatment, enabling personalized plans & combo therapies. #BreastCancerResearch #Immunotherapy #TNBC | Heather McArthur, MD, MPH, FASCO hubs.li/Q03b1HM-0

🙌Hey UTSW Simmons Cancer Center UT Southwestern Medical Center UTSWCancerBio UTSW Hematology & Oncology UTSW Science UTSW Department of Pathology Mol Biology Dept UTSW UTSW Immunology don't miss our next #KomenBreastCancerForum feat. Dr. Taha Merghoub Taha Weill Cornell Medicine *in person* Apr 16 #immunotherapy host Heather McArthur, MD, MPH

New📰in Therapeutic Advances in Medical Oncology👉TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (#DatoDXd) plus #durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer

Congratulations Alexis LeVee, MD! Such a pleasure to collaborate with you!! Looking forward to celebrating your many future successes!!

TDXd + pertuzumab improves PFS in 1st line DB-09! #HER2 #bcsm OncoAlert Oncology Brothers astrazeneca.com/media-centre/p…

Discussing adjuvant therapy as well as post mastectomy radiation. And who better to talk about all this than this panel Sara Tolaney Heather McArthur, MD, MPH, FASCO MD Education

What is the cause of ADC-related ILD? Spoiler: most likely not the antibody target (e.g. not HER2). New data confirms prior observations that T-DXd affects alveolar macrophages (AM) via Fc–FcγR engagement, triggering immune activation and ultimately ILD. aacrjournals.org/cancerres/arti…

Hear Erika Hamilton, MD of Sarah Cannon Docs, Heather McArthur, MD, MPH, FASCO of UT Southwestern Medical Center, and Kelly McCann, MD, PhD of UCLA discuss sequencing for HER2+ metastatic breast cancer after progression on first-line therapy.. Watch more here: hubs.li/Q03n-vRJ0

Love that Conquer Cancer, the ASCO Foundation managed to capture in the video below this simply magical moment when Alexis LeVee, MD won her ASCO YIA! It has been a joy to co-mentor this superstar in #breastcancer w Heather McArthur, MD, MPH UTSW Simmons Cancer Center (Heather, TY! As a #kidneycancer doc I was way out of my

My poster neighbors— “The study was negative, but the friendship was positive” Heather McArthur, MD, MPH, FASCO Michail ignatiadis #ASCO25

So proud of you Alexis LeVee, MD! Heather McArthur, MD, MPH, FASCO #ASCO25

🚨 If you're as serious about breast cancer care as Reshma Mahtani, Alan Baik, Antonio Giordano, MD PhD, Stephanie Graff, MD, FACP, FASCO, Claudine Isaacs, Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸, Heather McArthur, MD, MPH, FASCO, Kelly McCann, MD, PhD, Olufunmilayo Olopade, Kristin E. Rojas MD, FACS, FACOG, Dr Sarah Sammons, Rebecca Shatsky, MD, Joyce O'Shaughnessy, MD then you won't miss #PBCCLive25 in DC! It's the

ASCO dropped the data, now our experts help you take it from podium to practice. Watch now for concise recaps of top trials from #ASCO25. 📈 Top takeaways 🩺Real-world application 🇨🇦 Multiple tumour sites, CDN perspective. 📹 ow.ly/xCwZ50W5LKI Sharlene Gill, MD, MPH, MBA, FASCO Nimira Alimohamed